Zenta Group Receives Nasdaq Bid Price Deficiency Notice

The Macau-based consulting and fintech firm must regain a US$1.00 minimum closing bid price by May 10, 2027.

Updated on Nov. 12, 2026 in Corporate Finance

Zenta Group Receives Nasdaq Bid Price Deficiency Notice

Zenta Group Company Limited received a Nasdaq Deficiency Letter dated November 11, 2026, after its Class A ordinary shares closed below the US$1.00 minimum bid price for 31 consecutive business days. The letter has no current effect on the listing or trading of the shares on Nasdaq.

Why it matters

The notice starts a 180-calendar-day compliance period under Nasdaq Listing Rule 5810(c)(3)(A), during which the company must close at or above US$1.00 for ten consecutive business days to regain compliance. The company says it will take all reasonable measures to do so and may be eligible for additional time if it does not regain compliance by the deadline.

The Class A ordinary shares closed below the US$1.00 minimum bid price for 31 consecutive business days, against a requirement of ten consecutive business days at or above US$1.00 to regain compliance. The source does not disclose the closing prices during that period or the company's plan to restore the share price.

The players

Zenta Group Company Limited

A diversified consulting and fintech solutions provider based in Macau, founded in 2019, with a client base concentrated in China's Greater Bay Area.

Nasdaq

The US stock exchange that issued the Deficiency Letter and sets the minimum bid price and compliance rules under its Listing Rules.

The details

Nasdaq staff issued the Deficiency Letter under Nasdaq Listing Rule 5550(a)(2) on November 11, 2026, and Zenta Group announced receipt the following day. The company, founded in 2019 and based in Macau, has re-aligned its operations around AI and data solutions.

Timeline

  1. November 11, 2026: Nasdaq issues the Deficiency Letter.

  2. November 12, 2026: Zenta Group announces receipt of the letter.

  3. May 10, 2027: End of the 180-day period to regain compliance.

Market Dynamics

The 180-day cure period under Nasdaq Listing Rule 5810(c)(3)(A) gives issuers that fall below the US$1.00 minimum bid price a defined window to restore compliance before further listing steps. Zenta Group's notice follows that standard framework, and the company may seek additional time if it does not meet the May 10, 2027 deadline.

Holders of Zenta Group's Class A ordinary shares face the possibility of delisting if the price does not recover to US$1.00 for ten consecutive business days before the compliance deadline. The Deficiency Letter has no current effect on trading, so shares continue to trade on Nasdaq while the cure period runs.

The takeaway

A bid price notice is a compliance warning with a defined cure period, not an immediate trading halt, so investors should track whether the share price holds above US$1.00 through the period ending May 10, 2027.

What happens next

Zenta Group has until May 10, 2027 to regain compliance with the Nasdaq minimum bid price requirement, and may be eligible for additional time if it does not do so by that date.

Further reading

For more on how listed companies handle exchange requirements, see Corporate Finance.

Source note: This article includes information reported by The Manila times.